central nervous system

News

Is AbbVie planning an epic Gilgamesh takeover?

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

rofessor John Atack and Professor Simon Ward, from Cardiff University’s Medicines Discovery Institute

Welsh biotech Draig emerges with $140m in financing

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

News

After rebuffing Biogen, Sage pairs off with Supernus

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.

News

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

News

NeOnc Technologies' founder, chief executive and chief scientific officer Thomas Chen

NeOnc Technologies has another go at a Nasdaq listing

US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the CNS.

News

Seaport docks $225m for its improved neuropsychiatry drugs

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the developme

Is AbbVie planning an epic Gilgamesh takeover?

Welsh biotech Draig emerges with $140m in financing

After rebuffing Biogen, Sage pairs off with Supernus

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

NeOnc Technologies has another go at a Nasdaq listing

Seaport docks $225m for its improved neuropsychiatry drugs

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

central nervous system

Editor's Picks